この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
ビジネス · 2007/1/301 分で読めます
Indevus Pharmaceuticals, Inc.; Withdrawal of Approval of a New Drug Application
ローカル自動翻訳 · 情報源の原言語
概要
The Food and Drug Administration (FDA) is withdrawing approval of a new drug application (NDA) for REDUX (dexfenfluramine hydrochloride (HCl)) Capsules held by Indevus Pharmaceuticals, Inc. (Indevus), 33 Hayden Ave., Lexington, MA 02421-7971. Indevus has requested that approval of this application be withdrawn because the product is no longer marketed, thereby waiving its opportunity for a hearing.
情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →